SCHEDULE 13G/A: BlackRock Reduces Stake in Black Diamond Therapeutics to 4.5%

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.5% beneficial ownership stake in Black Diamond Therapeutics, Inc. as of March 31, 2025, indicating a reduction from a previously reportable position.

Summary

• BlackRock, Inc. reported beneficial ownership of 2,523,521 shares of Black Diamond Therapeutics, Inc. common stock.
• This represents 4.5% of the outstanding common stock of Black Diamond Therapeutics, Inc.
• BlackRock, Inc. holds sole voting power over 2,488,343 shares and sole dispositive power over 2,523,521 shares.
• The filing is an Amendment No. 1 to Schedule 13G, indicating a change from a previous filing.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 4

Explanation: The filing indicates a reduction in BlackRock's beneficial ownership to below 5%, which can be interpreted as a slight negative signal regarding institutional confidence, although it is a routine disclosure for a large asset manager.

Positives

• BlackRock, a major institutional investor, continues to hold a significant, albeit reduced, stake in Black Diamond Therapeutics, indicating ongoing, passive investment interest.
• The holding is certified as being for investment purposes in the ordinary course of business, not for control, suggesting a passive investment strategy.

Negatives

• BlackRock's beneficial ownership has decreased to 4.5%, falling below the 5% threshold, which typically implies a reduction from a previously higher, reportable stake.

Risks

• The reduction in BlackRock's beneficial ownership to below 5% could be interpreted by the market as a decrease in institutional confidence or a portfolio rebalancing, potentially leading to negative sentiment or share price pressure for Black Diamond Therapeutics, Inc.

Future Outlook

NA

Management Comments

• "In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

This filing is a routine disclosure of institutional ownership and does not provide broader industry trends or specific insights into the biotechnology or pharmaceutical sector in which Black Diamond Therapeutics operates.

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret the reduction in BlackRock's stake as a signal of decreased institutional interest, potentially leading to negative sentiment or price pressure for Black Diamond Therapeutics shares.

Key Dates

Recommendation

Keywords

BlackRock, Black Diamond Therapeutics, SEC filing, Schedule 13G, beneficial ownership, institutional investment, common stock, equity stake